Hims & Hers Health (HIMS) is back in focus after regulators accused the telehealth company of deceptive subscription practices and improper sharing of sensitive health data. This has prompted fresh questions around legal risk and customer trust.

Against this regulatory backdrop, Hims & Hers Health’s share price has been volatile, with a 1-day share price return of 6.13% but a year-to-date share price return that is down 5.24%. The 3-year total shareholder return of about 3.7x indicates that long-term holders have still seen strong gains. However, the 1-year total shareholder return declined 28.24%, which suggests that sentiment and momentum have cooled as legal and customer trust risks have come into sharper focus.

Compare how Hims & Hers Health’s regulatory and customer trust issues stack up against other companies with stronger balance sheets and fundamentals using our curated list of solid balance sheet and fundamentals (50 results).

After a sharp pullback over the past year and a quick one-day bounce, investors may be weighing whether it makes more sense to step into Hims & Hers Health now or wait for legal and trust risks to settle before paying a higher price. The valuation work starts from that question.

Most Popular Narrative: 81.7% Undervalued

Against the current share price of $31.66, the most followed valuation narrative on Hims & Hers Health points to a fair value of $173.02. This implies a large gap that the market has not priced in according to that view.

Over the long term (10yrs), Hims & Hers has an unusually large addressable market ahead of it. The company’s growth is described along three reinforcing dimensions:

• Expanding market size, with digital healthcare adoption continuing to grow globally

• Category expansion, including new offerings such as hormonal health, longevity, and sleep

• International scaling, with multiple geographies already in the pipeline (e.g. Brazil, Australia)

Want to see how this user, Deep_Insights, translates those growth layers into a fair value far above today’s share price? The key ingredients combine revenue expansion, margin assumptions and a premium future earnings multiple into one aggressive playbook. It may also be useful to explore which moving part matters most in that $173.02 figure and how sensitive the narrative is to changes in those inputs.

Result: Fair Value of $173.02 (UNDERVALUED)

However, this Hims & Hers Health narrative could be knocked off course if regulatory findings escalate into costly settlements, or if subscriber growth slows as trust concerns weigh on sign ups.

Next Steps

If this mix of concern and optimism around Hims & Hers Health feels familiar, act quickly and look at the numbers yourself to shape a view that fits your risk tolerance. To see both sides of the story in one place, start with 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Hims & Hers Health?

Do not stop your research with Hims & Hers Health. Broaden your watchlist now so you are not chasing opportunities after they have already moved.

• Spot potential mispricings early by scanning companies that pass our quality and value filters using the 46 high quality undervalued stocks.
• Build a steadier income stream by reviewing stocks that feature in the 12 dividend fortresses.
• Reduce downside surprises by focusing on companies highlighted in the 76 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.